Digital Health Roundup: CES Biggest Hits; Apple Versus Masimo; Insulet Recalls Diabetes App
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sensors in the newer Apple Watch models.
You may also be interested in...
Dexcom COO On Stelo CGM Plans, Apple Watch Developments, And Why Non-Invasive Glucose Monitoring Still Leaves Much To Desire
Exec Chat: Dexcom’s COO Jake Leach joined a panel discussion on the future of biosensing at CES 2024, where biowearables and glucose tech ranked among hot topics. He also spoke to Medtech Insight about plans for the company’s new CGM called Stelo, designed for people with type 2 diabetes who do not use insulin, Dexcom’s work with Apple to enable CGM users, and non-invasive monitoring prospects.
After a short import ban, Apple is modifying its watches to remove the pulse oximetry technology that was ruled to violate several Masimo patents.
CES Roundup: Holoportation, Empathic Robot, Aging Suit, Bionic Prosthetic Arm, Headband For Better Sleep
In this second roundup from CES, Medtech Insight shines the light on Proto Hologram’s many use cases in health care, Intuition Robotics’ ElliQ robot to help the elderly feel less lonely, MIT AgeLab’s Aging Suit, Siemens/Unlimited Tomorrow’s partnership on a bionic prosthetic arm, and Earable Neuroscience’s Frenz Brainband to promote better sleep.